Clinical trial
A Double-Blind, Placebo-Controlled, Multi-Center, Phase II, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YA-101 in Subjects With Multiple System Atrophy
NCT06848231 is registered in ClinicalTrials.gov with Dasher Neuroscience Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled, Multi-Center, Phase II, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YA-101 in Subjects With Multiple System Atrophy
- Lead sponsor
- Dasher Neuroscience Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- March 3, 2025
- Completion date
- December 31, 2027
- Enrollment
- 75 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.